Table 2.
Primary end point data comparison
| Number | group | case | Follow-up time/ recurrence case | |||
|---|---|---|---|---|---|---|
|
| ||||||
| 3 months | 6 months | 12 months | 24 months | |||
| 1 | p16+/ki67+ | 509 | 3 (0.59%) | 16 (3.1%) | 20 (3.9%) | 50 (9.8%) |
| 2 | P16+/ki67- | 601 | 3 (0.50%) | 10 (1.66%) | 11 (1.83%) | 53 (8.82%) |
| 3 | P16-/ki67+ | 403 | 0 (0) | 7 (1.74%) | 8 (1.99%) | 35 (8.67%) |
| 4 | P16-/ki67- | 387 | 0 (0) | 5 (1.29%) | 6 (1.55%) | 11 (2.84%) |
| Statistical index | ||||||
Note: The number of recurrent cases changed with the prolongation of follow-up time in all four groups. The recurrence rate of group 1 was higher than that of other 3 groups. In comparison with group 4, the 24 month recurrence rate in group 1 was significantly higher than that in group 4 (P<0.05). In the comparison between group 1, 2, group 1, 3, the P values were all >0.05, but the recurrence rate increased.